Related Experiment Video

Updated: May 18, 2026

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels
05:31

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels

Published on: August 7, 2017

Exploring the characteristics of children with obstructive adenoid responding to mometasone fuorate monohydrate:

Mohamed A Bitar1, Lorice Mahfoud, Jihad Nassar

  • 1Department of Otolaryngology Head and Neck Surgery, American University of Beirut Medical Center, PO Box 11-0236/A52, Beirut, Lebanon. mb36@aub.edu.lb

European Archives of Oto-Rhino-Laryngology : Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : Affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
|September 27, 2012
PubMed

Insights

Mometasone furoate monohydrate nasal spray effectively reduced obstructive adenoids in children. The treatment improved symptoms and obstruction, with effects independent of age or allergic rhinitis severity.

Area of Science:

  • Otorhinolaryngology
  • Pediatric Allergy
  • Pharmacology

Background:

  • Adenoid obstruction significantly impacts children's health.
  • Current treatment options for obstructive adenoids are limited.
  • Mometasone furoate monohydrate nasal spray is a potential therapeutic agent.

Purpose of the Study:

  • To evaluate the efficacy of mometasone furoate monohydrate nasal spray in children with obstructive adenoids.
  • To identify predictors of treatment response.
  • To assess the impact on allergic rhinitis and obstructive symptoms.

Main Methods:

  • Pilot study involving children aged 2-11 years with >50% adenoid obstruction.
  • Daily administration of 100 μg mometasone furoate monohydrate nasal spray.
  • Clinical and endoscopic evaluations at baseline, 6, and 12 weeks, compared to a control group.

Main Results:

  • Significant reduction in adenoidal obstruction (58%) and obstructive symptoms (56%) within 6 weeks (P < 0.05).
  • Marked improvement in allergic rhinitis scores (75%) (P < 0.05).
  • Endoscopic obstruction decreased from 85% to 61% (P < 0.05); no significant changes after 6 weeks.

Conclusions:

  • Mometasone furoate monohydrate nasal spray is effective for treating obstructive adenoids in children.
  • Treatment benefits were observed regardless of patient age, allergic rhinitis presence, or symptom severity.
  • No adverse effects were reported, suggesting a favorable safety profile.

More Related Videos

Assessment of Respiratory Function in Conscious Mice by Double-chamber Plethysmography08:58

Assessment of Respiratory Function in Conscious Mice by Double-chamber Plethysmography

Published on: July 10, 2018

Related Concept Videos

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics01:23

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics

Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla.  Benzonatate operates peripherally within the respiratory tract by anesthetizing...
Adrenergic Agonists: Mixed-Action Agents01:28

Adrenergic Agonists: Mixed-Action Agents

Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Upper Respiratory Drugs: Decongestants01:27

Upper Respiratory Drugs: Decongestants

Decongestants are a class of medications used primarily to alleviate nasal congestion, a common symptom resulting from allergies, colds, sinusitis, and other upper respiratory tract infections. These drugs work by activating α-adrenergic receptors, constricting small blood vessels in the nasal membranes. This action results in the opening of clogged nasal passages, thereby facilitating sinus drainage and relieving congestion.
Most decongestants are readily available over-the-counter in various...
Antiasthma Drugs: Methylxanthines01:24

Antiasthma Drugs: Methylxanthines

Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Asthma III: Clinical Manifestations01:13

Asthma III: Clinical Manifestations

Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...